Pilot study of low- vs. high-dose Rosuvastatin in minor heart attack patients and healthy controls: assessment of skin microvascular blood flow.
- Conditions
- Peripheral microvascular dysfunction in non-ST segment elevation myocardial infarction (NSTEMI).Cardiovascular - Coronary heart disease
- Registration Number
- ACTRN12613000575730
- Lead Sponsor
- yell McEwin Hosptial Department of Cardiology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- All
- Target Recruitment
- 36
Post-menopausal women (STRAW +10 definition) and age-matched men
NSTEMI group only - Evidence of NSTEMI: Electrocardiographic ST-segment depression or prominent T-wave inversion and/or positive biomarkers of necrosis (e.g., troponin) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or anginal equivalent)
Current statin therapy
Skin pathology on volar forearms
Previous myocardial infarction or coronary artery bypass grafting
Known serious or hypersensitivity reactions to statin, anti-platelet agents (aspirin or clopidogrel), or heparin
Cardiogenic shock or symptomatic hypotension or sitting SBP < 95mmHg
Congestive heart failure (NYHA Class III or IV) or LVEF < 35%
Inability to provide informed consent
Non-English speaking
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in peripheral subcutaenous microvascular reactivity as assessed by laser Doppler flowmetry.[After 7 days Rosuvastatin treatment.]
- Secondary Outcome Measures
Name Time Method Percent change in blood low-density lipoprotein (LDL) levels.[After 7 days Rosuvastatin treatment.]